Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.41 |
| ▸ | RXRA | P19793 | 6/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209857 | 1.00 | NR1H2 (0.41) | NR1H2NR1H3RXRAABCB1HCRTR2 | |
| SCHEMBL5783560 | 1.00 | NR1H2 (0.41) | NR1H2NR1H3RXRAABCB1HCRTR2 | |
| SCHEMBL8157917 | 0.90 | MEN1 (0.40) | MEN1KMT2ARORC | |
| SCHEMBL8157922 | 0.90 | MEN1 (0.40) | MEN1KMT2ARORC | |
| SCHEMBL8459509 | 0.83 | CHRM2 (0.37) | MEN1KMT2AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL9024216 | 0.79 | NR1H2 (0.47) | NR1H2NR1H3RXRAABCB1HCRTR2 | |
| SCHEMBL8156074 | 0.78 | NR1H2 (0.37) | NR1H2NR1H3RXRAABCB1HCRTR2 | |
| SCHEMBL8156067 | 0.78 | NR1H2 (0.37) | NR1H2NR1H3RXRAABCB1HCRTR2 | |
| SCHEMBL7919390 | 0.78 | NR1H2 (0.39) | NR1H2NR1H3RXRAABCB1HCRTR2 | |
| SCHEMBL8156075 | 0.78 | NR1H2 (0.37) | NR1H2NR1H3RXRAABCB1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929554-B1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-0942733-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2005-04-27 | — | — | EP | disclosed |
| EP-0941093-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME (GB) | 2005-02-09 | — | — | EP | disclosed |
| EP-0941092-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2004-12-29 | — | — | EP | disclosed |
| EP-0942732-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6613765-B1 | Administering compounds such as 2-(1-(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4 -triazolo)methyl)morpholine; sustained release antidepressants with side effect reduction | MERCK SHARP & DOHME LIMITED | 2003-09-02 | — | — | US | disclosed |
| US-6271230-B1 | ADMINISTERING NEUROKININ RECEPTOR ANTAGONIST | MERCK SHARP & DOHME LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| US-6172077-B1 | TACHYKININ INHIBITORS; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIEMETICS; NEURALGIA, HEADACHES | MERCK SHARP & DOHME LTD. (GB) | 2001-01-09 | — | — | US | disclosed |
| US-6156749-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
| US-6114315-A | ORAL ADMINISTERING; SIDE EFFECT REDUCTION | MERCK SHARP & DOHME LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| US-6090819-A | Use of NK-1 receptor antagonists for treating mania | MERCK SHARP & DOHME, LTD. (GB) | 2000-07-18 | — | — | US | disclosed |
| US-6087348-A | TREATING PHYSIOLOGICAL DISORDERS OR PSYCHOLOGICAL DISORDERS WITH NEUROKININ 1 (SUBSTANCE P) RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ORAL ONCE-A-DAY MEDICAMENT | MERCK SHARP & DOHME LTD. (GB) | 2000-07-11 | — | — | US | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| US-6046195-A | Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | disclosed |
| US-5977104-A | Use of NK-1 receptor antagonists for treating bipolar disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| US-5952315-A | TREATING PHYSIOLOGICAL DISORDERS, DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS ANXIETY, DEPRESSION AND PSYCHOSIS WITH AN ANTIDEPRESSANT | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5952330-A | A HETEROCYCLE-ALKYLMORPHOLINES FOR TREATING PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5929054-A | Use of NK-1 receptor antagonists for treating sexual dysfunctions | MERCK SHARP (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5925627-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5919781-A | Use of NK-1 receptor antogonists for treating substance use disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-06 | — | — | US | disclosed |